Barclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PT

Puma Biotechnology, Inc. (NASDAQ:PBYI) is one of the top most undervalued biotech stocks to buy now. In a report released on August 8, Gena Wang from Barclays maintained a Sell rating on Puma Biotechnology, Inc. (NASDAQ:PBYI) and set a price target of $2.00.

The rating update came after Puma Biotechnology, Inc. (NASDAQ:PBYI) reported its fiscal Q2 2025 results on August 7. Product revenue net for fiscal Q2 2025 came up to $49.2 million, up from $44.4 million in fiscal Q2 2024.

The product revenue net consisted solely of revenue from sales of NERLYNX, which is Puma Biotechnology, Inc.’s (NASDAQ:PBYI) first commercial product.

Product revenue net in the first six months of 2025 was $92.3 million, up from $84.6 million in the same time period in 2024.

Puma Biotechnology, Inc. (NASDAQ:PBYI) is a biopharmaceutical company involved in the acquisition and development of innovative products to treat different kinds of cancers.

The company’s focus is on the in-licensing drug candidates that are either in the process of or have already obtained initial clinical testing to treat cancer. It then endeavors to develop these drug candidates further for commercial use.

While we acknowledge the potential of PBYI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.